Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Zalcberg JR, et al. Among authors: brown m. Eur J Cancer. 2005 Aug;41(12):1751-7. doi: 10.1016/j.ejca.2005.04.034. Eur J Cancer. 2005. PMID: 16098458 Clinical Trial.
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Verweij J, et al. Among authors: brown m. Eur J Cancer. 2003 Sep;39(14):2006-11. Eur J Cancer. 2003. PMID: 12957454 Clinical Trial.
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT; EORTC Soft Tissue and Bone Sarcoma Group. Debiec-Rychter M, et al. Among authors: brown m. Eur J Cancer. 2004 Mar;40(5):689-95. doi: 10.1016/j.ejca.2003.11.025. Eur J Cancer. 2004. PMID: 15010069 Clinical Trial.
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR. Van Glabbeke M, et al. Among authors: brown m. J Clin Oncol. 2005 Aug 20;23(24):5795-804. doi: 10.1200/JCO.2005.11.601. J Clin Oncol. 2005. PMID: 16110036 Clinical Trial.
A contact binary satellite of the asteroid (152830) Dinkinesh.
Levison HF, Marchi S, Noll KS, Spencer JR, Statler TS, Bell JF 3rd, Bierhaus EB, Binzel R, Bottke WF, Britt D, Brown ME, Buie MW, Christensen PR, Dello Russo N, Emery JP, Grundy WM, Hahn M, Hamilton VE, Howett C, Kaplan H, Kretke K, Lauer TR, Manzoni C, Marschall R, Martin AC, May BH, Mottola S, Olkin CB, Pätzold M, Parker JW, Porter S, Preusker F, Protopapa S, Reuter DC, Robbins SJ, Salmon J, Simon AA, Stern SA, Sunshine JM, Wong I, Weaver HA, Adam C, Ancheta S, Andrews J, Anwar S, Barnouin OS, Beasley M, Berry KE, Birath E, Bolin B, Booco M, Burns R, Campbell P, Carpenter R, Crombie K, Effertz M, Eifert E, Ellis C, Faiks P, Fischetti J, Fleming P, Francis K, Franco R, Freund S, Gallagher C, Geeraert J, Gobat C, Gorgas D, Granat C, Gray S, Haas P, Harch A, Hegedus K, Isabelle C, Jackson B, Jacob T, Jennings S, Kaufmann D, Keeney BA, Kennedy T, Lauffer K, Lessac-Chenen E, Leonard R, Levine A, Lunsford A, Martin T, McAdams J, Mehall G, Merkley T, Miller G, Montanaro M, Montgomery A, Murphy G, Myers M, Nelson DS, Ocampo A, Olds R, Pelgrift JY, Perkins T, Pineau J, Poland D, Ramanan V, Rose D, Sahr E, Short O, Solanki I, Stanbridge D, Sutter B, Talpas Z, Taylor H, Treiu B, Ver… See abstract for full author list ➔ Levison HF, et al. Among authors: brown me. Nature. 2024 May;629(8014):1015-1020. doi: 10.1038/s41586-024-07378-0. Epub 2024 May 29. Nature. 2024. PMID: 38811709
Long COVID and cardiovascular disease: a prospective cohort study.
Lawson CA, Moss AJ, Arnold JR, Bagot C, Banerjee A, Berry C, Greenwood J, Hughes AD, Khunti K, Mills NL, Neubauer S, Raman B, Sattar N, Leavy OC, Richardson M, Elneima O, McAuley HJ, Shikotra A, Singapuri A, Sereno M, Saunders R, Harris V, Houchen-Wolloff L, Greening NJ, Harrison E, Docherty AB, Lone NI, Quint JK, Chalmers J, Ho LP, Horsley A, Marks M, Poinasamy K, Evans R, Wain LV, Brightling C, McCann GP; PHOSP-COVID Study Collaborative Group. Lawson CA, et al. Open Heart. 2024 May 27;11(1):e002662. doi: 10.1136/openhrt-2024-002662. Open Heart. 2024. PMID: 38802280 Free PMC article.
14,763 results
You have reached the last available page of results. Please see the User Guide for more information.